The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide).

The aim of this study was to determine the levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) after treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitor or dipeptidyl peptidase-4 (DPP4) inhibitor in patients with type-2 diabetes inadequately controlled by insulin, and to determine whether variation in ANP levels can explain favorable cardiovascular outcome.

Who Took Part

The abstract describes 56 patients taking part.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Topics PubMed links to this paper include Adamantane, Atrial Natriuretic Factor, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Dipeptides and Glucosides.

Author keywords: Diabète de type 2, Dipeptidyl peptidase-4 inhibitor, Glycémie, Inhibiteur de la dipeptidyl peptidase-4, Inhibiteur du cotransporteur-2 de sodium-glucose and Natriuretic peptide.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide) in 56 patients.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Annales d'endocrinologie), a journal based in France.

More context: the BNP (Nesiritide) compound page and the ANP (Atrial Natriuretic Peptide) compound page, all human trials.